You are here: Industry Insights > LAPC

News List

PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules firstwordpharma
August 24, 2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules, of 14,000,000 shares of the Company's common stock
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering firstwordpharma
August 03, 2021
PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company) today announced that The Nasdaq Stock Market LLC (Nasdaq) has approved the listing of the Company's common stock on Nasdaq.
PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer pharmaceutical-business-review
September 08, 2020
PharmaCyte Biotech has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).